Safety and efficacy of growth hormone replacement therapy in adults

Bibliography

• LI CH, EVANS HM, SIMPSON ME: Isolation and properties of anterior hypophyseal growth hormone. Biolog. Chem. (1945) 159:353–366.
   Web of Science ®Google Scholar
• LI CH, PAPKOFF H: Preparation and properties of growth hormone from human and monkey pituitary glands. Science (1956) 124:1293–1294.
   PubMed Web of Science ®Google Scholar
• RABEN MS: Treatment of a pituitary dwarf with human growth hormone. Clin. Endocrine]. Metab. (1958) 18:901–903.
   PubMed Web of Science ®Google Scholar
• RABEN MS: Growth hormone (concluded). 2 Clinical use of human growth hormone. N Engl. I Med. (1962) 266:82–86.
   Google Scholar
• RAITI S: Human growth hormone and Creutzfeldt-Jakob disease [editorial]. Ann. Intern. Med. (1985) 103:288–289.
   PubMed Web of Science ®Google Scholar
• SALOMON F, CUNEO RC, HESP R, PH S: The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N. Engl. I. Med. (1989) 321:1797–1803.
   PubMed Web of Science ®Google Scholar
• •First published controlled trials of GH replacement in adults.
   Google Scholar
• JORGENSEN JOL, PEDERSEN SA, THUESEN L et al.: Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet (1989) 1:1221–1225.
   PubMed Web of Science ®Google Scholar
• •First published controlled trials of GH replacement in adults.
   Google Scholar
• Human growth hormone (somatropin) in adults with growth hormone deficiency. 2003, National Institute for Clinical Excellence.
   Google Scholar
• ••UK guidelines for use of GHIn adults with GH deficiency.
   Google Scholar
• BURMAN P, BROMAN JE, HETTA J et al.: Quality of life in adults with growth hormone (GH) deficiency: response to treatment with recombinant human GH in a placebo-controlled 21-month trial. J. Clin. Endocrine]. Metab. (1995) 80:3585–3590.
   PubMed Web of Science ®Google Scholar
• HOLMES SJ, SHALET SM: Characteristics of adults who wish to enter a trial of growth hormone replacement. Chu. Endocrine]. (1995) 42:613–618.
   PubMed Web of Science ®Google Scholar
• MCGAULEY GA, CUNEO RC, SALOMON F, SONSKEN PH: Psychological well-being before and after growth hormone treatment in adults with growth hormone deficiency. Hormone Res. (1990) 33\(Suppl. 4):52–54.
   Google Scholar
• WALLYMAHMED ME, FOY P, MACFARLANE IA: The quality of life of adults with growth hormone deficiency: comparison with diabetic patients and control subjects. Chu. Endocrine]. (1999) 51:333–338.
   PubMed Web of Science ®Google Scholar
• HOLMES SJ, MCKENNA SP, DOWARD LC, HUNT SM, SHALET SM: Development of a questionnaire to assess the quality of life of adults with growth hormone deficiency. Endocrine]. Metab. (1995) 2:63–69.
   Google Scholar
• ATTANASIO AF, LAMBERTS SWJ, MATRANGA AMC et al: Adult growth hormone deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. I Chu. Endocrine]. Metab. (1997) 82:82–88.
   PubMed Web of Science ®Google Scholar
• TOOGOOD A, SHALET S: Growth hormone replacement therapy in the elderly with hypothalamic-pituitary disease: A dose finding study. I Chu. Endocrine] Metab. (1999) 84:131–136.
   PubMed Web of Science ®Google Scholar
• BESHYAH SA, HENDERSON A, NITHTHYANATHAN R et al: Metabolic abnormalities in growth hormone deficient adults: carbohydrate tolerance and lipid metabolism. Endocrine]. Metab. (1994) 1:173–180.
   Google Scholar
• BESHYAH SA, FREEMANTLE C, THOMAS E et al.: Abnormal body composition and reduced bone mass in growth hormone deficient hypopituitary adults. Chu. Endocrine] (1995) 42:179–189.
   PubMed Web of Science ®Google Scholar
• LONN L, KVIST, GRANGARD U, BENGTSSON BA, SJOSTROM L: CT-determined body composition changes with recombinant human growth hormone treatment to adults with growth hormone deficiency. Basic Life Science (1993) 60:229–231.
   PubMedGoogle Scholar
• HAFFNER SM, STERN MP, HAZUDA HP et al: Role of obesity and fat distribution in non-insulin-dependent diabetes mellitus in Mexican Americans and non-Hispanic whites. Diabetes Care (1986) 9:153–161.
   PubMed Web of Science ®Google Scholar
• KISSEBAH AH, VYDELINGUM N, MURRAY R et al: Relation of body fat distribution to metabolic complications of obesity. J. Chu. Endocrine]. Metabol (1982) 54:254–260.
   PubMed Web of Science ®Google Scholar
• BESHYAH SA, JOHNSTON DG: Cardiovascular disease and risk factors in adults with hypopituitarism. Clin. Endocrine]. (1999) 50:1–15.
   PubMed Web of Science ®Google Scholar
• DE BOER H, BLOK GJ, VOERMAN HJ, PHILLIPS M, SCHOUTEN JA: Serum lipid levels in growth hormone deficient men. Metabolism (1994) 43:199–203.
   PubMed Web of Science ®Google Scholar
• VAHL N, JORGENSEN JO, HANSEN TB et al: The favourable effects of growth hormone (GH) substitution on hypercholesterolaemia in GH-deficient adults are not associated with concomitant reductions in adiposity. A 12 month placebo-controlled study. Int., J. Obes. Relat. Metab. Disord. (1998) 22:529–536.
   Google Scholar
• CUNEO RC, SALOMON F, WATTS GE HESP R, SONKSEN PH: Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. Metabolism (1993) 42:1519–1523.
   PubMed Web of Science ®Google Scholar
• ROSEN T, EDEN S, LARSON G, WILHELMSEN L, BENGTSSON BA: Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol (1993) 129:195–200.
   PubMedGoogle Scholar
• SANMARTI A, LUCAS A, HAWKINS F, WEBB SM, ULIED A: Observational study in adult hypopituitary patients with untreated growth hormone deficiency (ODA study) Socio-economic impact and health status. Collaborative ODA (Observational GH Deficiency in Adults) Group. Eur.j Endocrinol. (1999) 141:481–489.
   Google Scholar
• KLIBANSKI A: Growth hormone and cardiovascular risk markers. Growth Harm. IGF Res. (2003) 13 (Suppl.) :S109–S115.
   Google Scholar
• LEONSSON M, HULTHE J, JOHANNSSON G et al: Increased Interleukin-6 levels in pituitary-deficient patients are independently related to their carotid intima-media thickness. Clin. Endocrinol (2003) 59:242–250.
   PubMed Web of Science ®Google Scholar
• PFEIFER M, VERHOVEC R, ZIZEK B et al.: Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. I Clin. Endocrinol. Metab. (1999) 84:453–457.
   PubMed Web of Science ®Google Scholar
• ROSEN T, BENGTSSON B: Premature mortality due to cardiovascular disease in hypopituitarism. Lancet (1990) 336:285–288.
   PubMed Web of Science ®Google Scholar
• ••Describes increased mortalityIn hypopituitary patients.
   Google Scholar
• TOMLINSON JW, HOLDEN N, HILLS RK et al.: Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet (2001) 357:425–431.
   PubMed Web of Science ®Google Scholar
• ••Identifies some of the factors contributing to increased mortality.
   Google Scholar
• BATES AS, VAN'T HOFF W, JONES PJ, CLAYTON RN: The effect of hypopituitarism on life expectancy. I Clin. Endocrinol. Metab. (1996) 81:1169–1172.
   PubMed Web of Science ®Google Scholar
• BULOW B, HAGMAR L, MIKOCZY Z, NORDSTROM CH, ERFURTH EM: Increased cerebrovascular mortality in patients with hypopituitarism. Endocrinol (1997) 46:75–81.
   Web of Science ®Google Scholar
• TOOGOOD AA: Cardiovascular risk, and mortality ill patients with growth hormone deficiency, in Growth hormone deficiency in adults: I 0 years of KIMS, R. Abs and U. Feldt-Rasmussen, Editors. 2004, Oxford Pharmagenesis: Oxford. p. 63–74.
   Google Scholar
• •Detailed review of cardiovascular risk factors in hypopituitarism and the effects of GH replacement.
   Google Scholar
• HOLMES SJ, ECONOMOU G, WHITEHOUSE RW, ADAMS JE, SHALET SM: Reduced bone mineral density in patients with adult onset growth hormone deficiency. Clin. Endocrinol Metab. (1994) 78:669–674.
   Google Scholar
• ATTANASIO AF, HOWELL S, BATES PC et al: Body composition, IGF-I and IGFBP-3 concentrations as outcome measures in severely GH-deficient (GHD) patients after childhood GH treatment: a comparison with adult onset GHD patients. I Clin. Endocrinol Metab. (2002) 87:3368–3372.
   PubMed Web of Science ®Google Scholar
• SHALET SM, SHAVRIKOVA E, CROMER M et al.: Effect of growth hormone (GH) treatment on bone in postpubertal GH-deficient patients: a 2-year randomized, controlled, dose-ranging study. Clin. Endocrinol Metab. (2003) 88:4124–4129.
   Google Scholar
• TOOGOOD AA, ADAMS JE, O'NEILL PA, SHALET SM: Elderly patients with adult onset growth hormone deficiency are not osteopenic. I Clin. Endocrinol. Metab. (1997) 82:1462–1466.
   PubMed Web of Science ®Google Scholar
• ROSEN T, WILHELMSEN L, LANDIN-WILHELMSEN K, LAPPAS G, BENGTSSON B: Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur. I Endocrinol (1997) 137:240–245.
   PubMed Web of Science ®Google Scholar
• WUSTER C, ABS R, BENGTSSON BA et al.: The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. I Bone Miner. Res. (2001) 16:398–405.
   PubMed Web of Science ®Google Scholar
• TOOGOOD AA, BEARDWELL CG, SHALET SM: The severity of growth hormone deficiency in adults with pituitary disease is related to the degree of hypopituitarism. Clin. Endocrinol (1994) 41:511–516.
   PubMed Web of Science ®Google Scholar
• GROWTH HORMONE RESEARCH SOCIETY: Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: Summary statement of the Growth Hormone Research Society workshop on adult growth hormone deficiency. I Clin. Endocrinol Metab. (1998) 83:379–381.
   PubMed Web of Science ®Google Scholar
• RAHIM A, TOOGOOD AA, SHALET SM: The assessment of growth hormone status in normal young adult males using a variety of provocative tests. Endocrinol (1996) 45:557–562.
   Web of Science ®Google Scholar
• NICOLSON A, TOOGOOD AA, RAHIM A, SHALET SM: The prevalence of severe growth hormone deficiency in adults who received growth hormone replacement in childhood. Clin. Endocrinol (1996) 44:311–316.
   PubMed Web of Science ®Google Scholar
• SHALET SM, TOOGOOD A, RAHIM A,BRENNAN BM: The diagnosis of growth hormone deficiency in children and adults. Endocr. Rev (1998) 19:203–223.
   PubMed Web of Science ®Google Scholar
• •Review of diagnostic criteria and methods used to identify patients with GH deficiency.
   Google Scholar
• BENGTSSON BA, JOHANNSSON G, SHALET SM, SIMPSON H, SONKEN PH: Treatment of growth hormone deficiency in adults. I Clin. Endocrinol Metab. (2000) 85:933–942.
   PubMed Web of Science ®Google Scholar
• CLAYTON PE, CUNEO RC, JUUL A et al.: Consensus statement on the management of the GH-treated adolescent in the transition to adult care. Eur. Endocrinol (2005) 152:165–170.
   PubMed Web of Science ®Google Scholar
• •Important for management of patients in adolescence.
   Google Scholar
• LAPIDUS L, BENGTSSON C, LARSSON B et al: Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Br. Med. (1984) 289:1257–1261.
   PubMed Web of Science ®Google Scholar
• BIGAARD J, TJONNELAND A, THOMSEN BL et al: Waist circumference, BMI, smoking, and mortality in middle-aged men and women. Obes. Res. (2003) 11:895–903.
   PubMedGoogle Scholar
• SESMILO G, BILLER BM, LLEVADOT J et al.: Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann. Intern. Med. (2000) 133:111–22.
   PubMed Web of Science ®Google Scholar
• COLAO A, DI SOMMA C, CUOCOLO A et al: Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency. I Clin. Endocrinol Metab. (2001) 86:1874–1881.
   PubMed Web of Science ®Google Scholar
• CHRISTOPHER M, HEW FL, OAKLEY M, RANTZAU C, ALFORD F: Defects of insulin action and skeletal muscle glucose metabolism in growth hormone-deficient adults persist after 24 months of recombinant human growth hormone therapy. I Clin. Endordnol. Metab. (1998) 83:1668–1681.
   PubMed Web of Science ®Google Scholar
• O'NEAL DN, KALFAS A, DUNNING PL et al: The effect of 3 months of recombinant human growth hormone (GH) therapy on insulin and glucose-mediated glucose disposal and insulin secretion in GH-deficient adults: a minimal model analysis. JClin. Endocrinol Metab. (1994) 79:975–983.
   PubMed Web of Science ®Google Scholar
• SVENSSON J, FOWELIN J, LANDIN K, BENGTSSON BA, JOHANSSON JO: Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. I Clin. Endocrinol Metab. (2002) 87:2121–2127.
   PubMed Web of Science ®Google Scholar
• WIERINGA G, TOOGOOD AA, RYDER WD et al.: Changes in lipoprotein(a) levels measured by six kit methods during growth hormone treatment of growth hormone-deficient adults. Growth Horm. IGF Res. (2000) 10:14–19.
   PubMed Web of Science ®Google Scholar
• GIBNEY J, WALLACE JD, SPINKS T et al.: The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. I Clin. Endordnol. Metab. (1999) 84:2596–2602.
   PubMed Web of Science ®Google Scholar
• BENGTSSON BA, KOPPESCHAAR HP, ABS R et al: Growth hormone replacement therapy is not associated with any increase in mortality. I Clin. Endocrinol Metab. (1999) 84:4291–4292.
   PubMed Web of Science ®Google Scholar
• JOHANSEN JS, PEDERSEN SA, JIRGENSEN JOL et al.: Effects of growth hormone on plasma bone gla protein in gh deficient adults. I Clia Endocrinol Metab. (1990) 70:916–919.
   PubMed Web of Science ®Google Scholar
• SCHLEMMER A, JOHANSEN JS, PEDERSEN SA et al.: The effect of growth hormone therapy on urinary pyridinoline cross-links in GH-deficient adults. Clin. Endocrinol (1991) 35:471–476.
   PubMed Web of Science ®Google Scholar
• JUUL A, PEDERSEN SA, SORENSEN S et al.: Growth hormone treatment increases serum insulin-like growth factor binding protein-3,bone isoenzyme alkaline phosphatase and forearm bone mineral content in oyung adults with GH deficiency of childhood onset. Fur. I Endordnol. (1994) 131:41–49.
   Web of Science ®Google Scholar
• WHITEHEAD HM, BOREHAM C, MCILRATH EM et al: Growth hormone treatment of adults with growth hormone deficiency: Results of a 13-month placebo controlled cross-over study. Clin. Endocrinol (1992) 36:45–52.
   PubMed Web of Science ®Google Scholar
• VANDEWEGHE M, TAELMAN P, KAUFMAN JM: Short and long-term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone-deficient males. Endordnol. (1993) 39:409–415.
   Web of Science ®Google Scholar
• VAN DER VEEN EA, NETELENBOS JC: Growth hormone (replacement) therapy in adults: Bone and calcium metabolism. Horm. Res. (1990) 33\(Suppl. 4):65–68.
   Google Scholar
• SARTORIO A, CONTI A, MONZANI M: New markers of bone and collagen turnover in children and adults with growth hormone deficiency. Postgrad. Med. J. (1993) 69:846–850.
   PubMed Web of Science ®Google Scholar
• BINNERTS A, SWART GR, WILSON JHP et al: The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition. Clia Endocrinol (1992) 37:79–87.
   PubMed Web of Science ®Google Scholar
• BESHYAH SA, THOMAS E, KYD P et al: The effect of growth hormone replacement therapy in hypopituitary adults on calcium and bone metabolism. Clin. Endocrinol (1994) 40:383–391.
   PubMed Web of Science ®Google Scholar
• AMATO G, CARELLA C, FAZIO S et al: Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. I Clia Endocrinol Metab. (1993) 77:1671–1676.
   PubMed Web of Science ®Google Scholar
• DEGERBLAD M, BENGTSSON B, BRAMNERT M et al: Reduced bone mineral density in adults with growth hormone deficiency: Increased bone turnover during 12 months of GH substitution therapy. Fur. I Endocrinol (1995) 133:180–188.
   Web of Science ®Google Scholar
• BALDUCCI R, TOSCANO V, PASQUINO AM et al.: Bone turnover and bone mineral density in young adult patients with hypopituitarism before and after long term growth hormone therapy. Fur. I Endordnol. (1995) 132:42–46.
   Web of Science ®Google Scholar
• KOTZMANN H, RIEDL M, BERNECKER P et al.: Effect of long-term growth hormone substitution therapy on bone mineral density and parameters of bone metabolism in adult patients with growth hormone deficiency. Cakil: Tissue Int. (1998) 62:40–46.
   PubMed Web of Science ®Google Scholar
• HOLMES SJ, WHITEHOUSE RW, SWINDELL R et al.: Effect of growth hormone replacement on bone mass in adults with adult onset growth hormone deficiency. Clin. Endocrinol (1995) 42:627–633.
   PubMed Web of Science ®Google Scholar
• O'HALLORAN DJ, TSATSOULIS A, WHITEHOUSE RW et al: Increased bone density after recombinant human growth hormone therapy in adults with isolated GH deficiency. I Clin. Endocrinol Metab. (1993) 76:1344–1348.
   PubMed Web of Science ®Google Scholar
• BRAVENBOER N, HOLZMANN P, DE BOER H et al.: The effect of growth hormone on histomorphometric indices of bone structure and bone turnover in GH deficient men. I Clin. Endocrinol Metab. (1997) 82:1818–1822.
   Google Scholar
• JOHANNSSON G, ROSEN T, BOSAEUS I, SJOSTROM L, BENGTSSON B-: Long term growth hormone treatment increases bone mineral content and density in patients with adult-onset growth hormone deficiency. I Clin. Endocrinol Metab. (1996) 81:2865–2873.
   PubMed Web of Science ®Google Scholar
• HOLMES SJ, WHITEHOUSE RW, ECONOMOU G et al: Further increase in forearm cortical bone mineral content after discontinuation of growth hormone replacement. Clin. Endocrinol (1995) 42:3–7.
   PubMed Web of Science ®Google Scholar
• BIERMASZ NR, HAMDY NA, PEREIRA AM, ROMIJN JA, ROELFSEMA F: Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study. Clin. Endocrinol (2004) 60:568–575.
   PubMed Web of Science ®Google Scholar
• BRYANT J, LOVEMAN E, CHASED et al.: Clinical effectiveness and cost-effectiveness of growth hormone in adults in relation to impact on quality of life: a systematic review and economic evaluation. Health Technol Assess. (2002) 6:1–106.
   Google Scholar
• HOLMES SJ, SHALET SM: Which adults develop side-effects of growth hormone replacement. Clin. Endocrinol (1995) 43:143–149.
   PubMed Web of Science ®Google Scholar
• WALLYMAHMED ME, FOY P, SHAW D et al: Quality of life, body composition and muscle strength in adult growth hormone deficiency: the influence of growth hormone replacement therapy for up to 3 years. Clin. Endocrinol (1997) 47:439–446.
   PubMed Web of Science ®Google Scholar
• HERNBERG-STAHL E, LUGER A, ABS R et al: Healthcare consumption decreases in parallel with improvements in quality of life during GH replacement in hypopituitary adults with GH deficiency. Clin. Endocrinol Metab. (2001) 86:5277–5281.
   Google Scholar
• ROSILIO M, BLUM WE EDWARDS DJ et al.: Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H). Clin. Endocrinol Metab. (2004) 89:1684–1693.
   Google Scholar
• HOLMES SJ, SHALET SM: Factors influencing the desire for long term growth hormone replacement in adults. Clin. Endocrinol (1995) 43:151–157.
   PubMed Web of Science ®Google Scholar
• MURRAY RD, SKILLICORN CJ, HOWELL SJ et al: Influences on quality of life in GH deficient adults and their effect on response to treatment. Clin. Endocrinol (1999) 51:565–573.
   PubMed Web of Science ®Google Scholar
• MURRAY RD, SKILLICORN CJ, HOWELL SJ et al.: Dose titration and patient selection increases the efficacy of GH replacement in severely GH deficient adults. Clin. Endocrinol (1999) 50:749–757.
   PubMed Web of Science ®Google Scholar
• DRAKE WM, HOWELL SJ, MONSON JP, SHALET SM: Optimizing gh therapy in adults and children. Endocr. Rev (2001) 22:425–50.
   PubMed Web of Science ®Google Scholar
• ••Discusses how best to optimiseGH replacement therapy in adults.
   Google Scholar
• MARDH G, LUNDIN K, BORG G, JONSSON B, LINDEBERG A: Growth hormone replacement therapy in adult hypopituitary patients with growth hormone deficiency: combined data from 12 European placebo-controlled clinical trials. Endocrinol Metab. (1994) l(Suppl. A):43–49.
   Google Scholar
• ROSEN CJ: Growth hormone, insulin-like growth factors, and the senescent skeleton: Ponce de Leon's Fountain revisited?' Cell. Biochem. (1994) 56:348–356.
   Web of Science ®Google Scholar
• CHIPMAN JJ, ATTANASIO AF, BIRKETT MA et al: The safety profile of GH replacement therapy in adults. Endocrinol (1997) 46:473–81.
   Web of Science ®Google Scholar
• FLORAKIS D, HUNG V, KALTSAS G et al: Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study. Endocrinol (2000) 53:453–459.
   Web of Science ®Google Scholar
• ORME SM, MCNALLY RJ, CART WRIGHT RA, BELCHETZ PE: Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. j Clin. Endocrinol Metab. (1998) 83:2730–2734.
   PubMed Web of Science ®Google Scholar
• EZZAT S, MELMED S: Clinical review 18: Are patients with acromegaly at increased risk for neoplasia?' Clin. Endocrinol. Metab. (1991) 72:245–249.
   Web of Science ®Google Scholar
• RENEHAN AG, BHASKAR P, PAINTER JE et al: The prevalence and characteristics of colorectal neoplasia in acromegaly. I Clin. Endocrinol. Metab. (2000) 85:3417–3424.
   PubMed Web of Science ®Google Scholar
• CHAN J, STAMPFER M, GIOVANNUCCI E et al: Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science (1998) 279:563–566.
   PubMed Web of Science ®Google Scholar
• HANKINSON S, WILLETT W, COLDITZ G et al: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet (1998) 351:1393–1396.
   PubMed Web of Science ®Google Scholar
• SVENSSON J, BENGTSSON BA: Safety of growth hormone replacement therapy in adults, in Growth Hormone Deficiency in Adults: 10 Years of KIMS, R. Abs and U. Feldt-Rasmussen (Eds) 2004, Oxford Pharmagenesis: Oxford. p. 315–322.
   Google Scholar
• •Reviews the safety of GH replacement therapy in adults.
   Google Scholar
• SWERDLOW AJ, REDDINGIUS RE, HIGGINS CD et al: Growth hormone treatment of children with brain tumors and risk of tumor recurrence.EndocrinolMetab. (2000) 85:4444–4449.
   PubMed Web of Science ®Google Scholar